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Proteomics-derived basal biomarker DNA-PKcs is associated
with intrinsic subtype and long-term clinical outcomes in
breast cancer
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Karama Asleh 1,2, Nazia Riaz
Torsten O. Nielsen 1 ✉

1,3

, Angela S. Cheng1, Dongxia Gao1, Samuel C. Y. Leung1, Meenakshi Anurag4 and

Precise biomarkers are needed to guide better diagnostics and therapeutics for basal-like breast cancer, for which DNA-dependent
protein kinase catalytic subunit (DNA-PKcs) has been recently reported by the Clinical Proteomic Tumor Analysis Consortium as the
most speciﬁc biomarker. We evaluated DNA-PKcs expression in clinically-annotated breast cancer tissue microarrays and correlated
results with immune biomarkers (training set: n = 300; validation set: n = 2401). Following a pre-speciﬁed study design per REMARK
criteria, we found that high expression of DNA-PKcs was signiﬁcantly associated with stromal and CD8 + tumor inﬁltrating
lymphocytes. Within the basal-like subtype, tumors with low DNA-PKcs and high tumor-inﬁltrating lymphocytes displayed the most
favourable survival. DNA-PKcs expression by immunohistochemistry identiﬁed estrogen receptor-positive cases with a basal-like
gene expression subtype. Non-silent mutations in PRKDC were signiﬁcantly associated with poor outcomes. Integrating DNA-PKcs
expression with validated immune biomarkers could guide patient selection for DNA-PKcs targeting strategies, DNA-damaging
agents, and their combination with an immune-checkpoint blockade.
npj Breast Cancer (2021)7:114 ; https://doi.org/10.1038/s41523-021-00320-x

INTRODUCTION
While gene expression proﬁling has reﬁned breast cancer
prognosis and helped guide treatment choices1–3, few advancements have been made in identifying practical biomarkers that
can aid in tailoring treatments for the aggressive basal-like
intrinsic subtype of breast cancer4–6.
The gene expression-deﬁned basal-like breast cancer subtype is
currently clinically approximated by triple-negative immunohistochemical (IHC) status, characterized by combined negativity for
estrogen receptor (ER), progesterone receptor, and human
epidermal growth factor receptor-2 (Her2). However, this IHC
deﬁnition identiﬁes a group with a heterogeneous biology7–9 that
consists of at least four major molecular subgroups termed basal
immune activated, basal immune suppressed, mesenchymal and
luminal androgen receptor10,11. These subgroups have been
repeatedly shown to differ in their clinical outcomes and exhibit
a complex repertoire of somatic mutations, highlighting the
complexity of guiding therapeutic choices for triple-negative
breast cancers, including those with basal-like molecular
biology7,10.
In an attempt to identify improved diagnostic tools and
therapeutic options for this aggressive group of cancers, more
precise basal biomarkers have been recently proposed based on
new proteomic proﬁling data. A mass spectrometry-based analysis
performed by the Clinical Proteomic Tumor Analysis Consortium
group using fresh frozen materials from 122 TCGA breast cancer
specimens reported DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) to be the most speciﬁc biomarker for the
basal-like subtype12,13.
DNA-PKcs, encoded by PRKDC, is a member of the phosphatidylinositol 3-kinase–related family of protein kinases that plays a

critical role in cell response to DNA damage and repair of doublestrand breaks14. In response to DNA damage, the catalytic subunit
of DNA-PKcs is recruited to the double-strand break site to bind to
the Ku70/Ku80 heterodimer and form the DNA-PK serine/
threonine-protein kinase complex15. This complex plays an
important role in DNA damage response (DDR) and maintenance
of genomic stability through the nonhomologous end-joining
DNA repair pathway16. The binding of DNA-PKcs further phosphorylates and coordinates the activation of other proteins that
mediate nonhomologous end-joining DNA repair17,18. Recently,
DNA-PKcs has been proposed as an actionable therapeutic target
for DNA damage in the breast and several other tumors types19–22
with DNA-PKcs inhibitors being actively assessed in clinical
trials14,23. These ﬁndings along with recent evidence supporting
the efﬁcacy of DNA-PKcs in preclinical models support the
development of DNA-PKcs targeting strategies in breast cancer24.
In the context of triple-negative breast cancer heterogeneity,
PRKDC has been reported to be highly expressed in the basal
immune activated and basal immune-suppressed molecular
subgroups, while being depleted in the luminal androgen
receptor and mesenchymal breast carcinomas11. DNA damage
and double-strand break repair pathways have been shown to be
speciﬁcally upregulated in basal-like breast cancers due to their
high aberrant activation resulting from the DDR deﬁcits, high
mutational load, and genomic instability that characterize these
tumors8,25,26.
In this study, we evaluated the prognostic capacity of the basal
biomarker DNA-PKcs on a large tissue microarray series representing early-stage breast cancer patients. Following a prespeciﬁed
study design, we tested the hypothesis that high expression of
DNA-PKcs identiﬁes cases with basal-like features and poor clinical
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outcomes. We further explored the value of combining DNA-PKcs
IHC assessment with key immune biomarkers in the context of
basal-like heterogeneity. In addition, we investigated the utility of
DNA-PKcs as a basal biomarker in ER-positive breast cancers,
correlating results with biological intrinsic gene expression
subtype and genomic data.
RESULTS
DNA-PKcs expression is associated with basal-like
characteristics, adverse clinicopathological features and poor
survival in the UBC series
A total of 300 cases were evaluable for DNA-PKcs expression by
immunohistochemistry (IHC) in the UBC series. Representative
images of IHC expression of DNA-PKcs are displayed in Fig. 1. High
expression of DNA-PKcs was found in 20.3% (n = 67) of cases and
was associated with features of the aggressive disease including
grade 3 histology, lymphovascular invasion, ER negativity, EGFR
expression, CK5/6 expression, high proliferation index (Ki-67 ≥
14%), and triple-negative status (Supplementary Table 1). DNAPKcs expression was signiﬁcantly higher in cases with the IHC core
basal phenotype (deﬁned as ER-negative, progesterone receptornegative, Her2 negative, and [EGFR + or CK5 + ])27 compared to
non-core basal cases (Fig. 2a and Supplementary Table 1).
Additionally, DNA-PKcs expression was associated with high
numbers of cytotoxic T-cells (CD8 + iTILs, Supplementary Table
1). When matching IHC expression data for DNA-PKcs with CD8 +
iTILs on the same tissue core, a weak but signiﬁcant correlation
was observed (Fig. 2b).
The median follow-up for the UBC cohort was 12.7 years;
tumors with high expression of DNA-PKcs were found to be
signiﬁcantly associated with lower breast cancer-speciﬁc survival
(HR 2.04, 95% CI 1.19–3.52, p = 0.01) when compared to cases
with low DNA-PKcs (Fig. 2c).
Validation of the prognostic signiﬁcance of DNA-PKcs in the
BC Cancer series
Observations from the UBC series cohort were next validated in
the larger, independent BC Cancer series cohort (Supplementary
Data 1) wherein the mean age at diagnosis was 58.9 years and the
median duration of follow-up was 12.5 years (Table 1).
Of the primary tumor samples, 2401 were interpretable for
DNA-PKcs immunostaining. The original version of the BC Cancer
series TMA had 3992 cases28,29, but since that time many cores
have been cut through and source blocks exhausted, such that
interpretable data for the current study could be generated for
2401 cases. Among these, high expression of DNA-PKcs was
observed in 25.7% (618/2401 cases) (Table 1). A signiﬁcant
association was observed between tumors with high expression
of DNA-PKcs and adverse pathological features including grade 3
histology, high Ki-67 proliferation index (deﬁned as ≥14%),
hormone receptor negativity, Her2 positivity, expression of basal
biomarkers including CK5/6, EGFR, and a triple-negative phenotype (p < 0.001) (Table 1). In addition, DNA-PKcs expression was
found to be signiﬁcantly associated with core basal tumors (p <
0.001) (Fig. 3a) (Table 1). Using prespeciﬁed criteria and the
scoring methodology as published by others30, we analyzed the
correlation of DNA-PKcs expression with inﬁltrating lymphocytes
(stromal H&E sTILs and CD8 + iTILs). We found that tumors
categorized with high DNA-PKcs expression were highly signiﬁcantly associated with the expression of these immune biomarkers
(p < 0.001) (Table 1). Further assessment of DNA-PKcs expression
revealed signiﬁcantly higher scores in cases characterized by high
H&E sTILs and CD8 + iTILs (Fig. 3b).
We next evaluated the prognostic signiﬁcance of DNA-PKcs
expression in the BC Cancer series, and conﬁrmed that cases with
high DNA-PKcs expression are associated with poor BCSS (HR 1.38,
npj Breast Cancer (2021) 114

95% CI 1.17–1.62; p < 0.001) (Fig. 3c). Upon stratiﬁcation by ER
status, high DNA-PKcs expression retained a signiﬁcant association
with poor BCSS in ER- tumors (HR 1.44, 95% CI 1.12–1.87; p =
0.005) compared to ER + tumors (HR 1.19, 95% CI 0.95–1.48; p =
0.13) (Supplementary Fig. 1a–1b).
Next, we performed multivariate analysis using Cox proportional hazards model to assess the independent prognostic
relevance of DNA-PKcs expression adjusted for clinicopathological
variables (age, tumor size, histological grade, axillary lymph node
status), breast cancer subtypes, and systemic treatments. High
expression of DNA-PKcs remained an independent prognostic
factor indicative of poor BCSS (HR 1.33, 95% CI 1.10–1.60; p =
0.002) (Table 2).
Prognostic stratiﬁcation of basal cases based on the
combination of DNA-PKcs and immune biomarkers
The core basal phenotype deﬁned by a 5-biomarker immunopanel
(ER-negative, progesterone receptor-negative, Her2 negative, and
[EGFR + or CK5 + ]) has been previously shown to more speciﬁcally identify cases with the basal-like gene expression subtype27
and to provide superior prognostic information when compared
to an IHC deﬁnition that is based simply on triple-negative
expression for the estrogen, progesterone and Her2 receptors31.
Thus, we speciﬁcally examined the prognostic signiﬁcance of
DNA-PKcs expression in the IHC based core basal (vs non-core
basal) subtype and found that tumors characterized by both high
expression DNA-PKcs and by a core basal phenotype displayed
the worst BCSS (HR 1.66, 95% CI 1.23–2.22; p = 0.001) compared to
other groups (Fig. 3d).
Given that PRKDC, the gene encoding for DNA-PKcs, is
characteristic of both the basal immune activated and basal
immune-suppressed RNA-based subgroups of triple-negative
breast cancer11, we investigated the prognostic signiﬁcance of
the combination of key immune biomarkers (sTILs and CD8 +
iTILs) and DNA-PKcs expression status within the core basal
subtype. We found that low DNA-PKcs expression concurrent with
the presence of stromal TILs correlated with superior survival in
the core basal tumors (HR 0.42, 95% CI 0.22–0.78; p = 0.005) (Fig.
4a). Similar results were observed when we used ≥30% as the
cutpoint for deﬁning high levels of H&E sTILs, a value used by
others in recently published studies32,33 (Supplementary Fig. 2).
The cytotoxic T-cell subset showed an even more marked
association with good prognosis: cases with low DNA-PKcs that
had high levels of CD8 + iTILs were associated with a signiﬁcantly
better BCSS (HR 0.26, 95% CI 0.13–0.55; p < 0.001) (Fig. 4b),
deﬁning a group of patients with disease-speciﬁc survival better
than 80% even 15 years after being diagnosed with triple-negative
breast cancer.
DNA-PKcs and mRNA PRKDC expression are associated with
PAM50 intrinsic subtype and poor clinical outcomes
To date, successful basal biomarkers that have been validated
against gold-standard gene expression assays are mostly limited
to the triple-negative breast cancer setting31 with very few
applicable in the context of ER positivity34,35. However, there is a
proven subset of basal-like gene expression in the literature that is
ER positive36–38. Thus, we aimed to assess the value of DNA-PKcs
as a basal marker on datasets with gene expression proﬁle data
that include ER-positive cases. We tested the association between
DNA-PKcs IHC expression and PAM50 intrinsic subtype on a set of
825 cases in the BC Cancer series previously proﬁled by
quantitative reverse transcription-polymerase chain reaction for
PAM50 gene expression39. The majority of these cases corresponded to clinically ER + patients that were treated with
adjuvant tamoxifen39; a total of 571 had available data for both
mRNA PAM50 intrinsic subtype and DNA-PKcs expression by IHC.
Basal-like PAM50 tumors were characterized by higher IHC scores
Published in partnership with the Breast Cancer Research Foundation
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a

IHC score = 0 (negative)

b

IHC score = 2 (negative)

c

IHC score = 6 (positive)

d
IHC score = 12 (positive)

Fig. 1 Representative images for nuclear expression of DNA-PKcs by immunohistochemistry. A case with negative staining for DNA-PKcs
(IHC score = 0) is shown in (a), a case with 10% positivity and weak intensity (IHC score = 2) is shown in (b), a case with 40% positivity and
moderate intensity (IHC score = 6) is shown in (c), and a case with 90% positivity and strong intensity (IHC score = 12) is shown in (d). The
images were acquired at 20× objective magniﬁcation (200× original magniﬁcation) for the tissue microarray cores. Scale bar of 100 µm is
shown. Abbreviations: IHC, immunohistochemistry.

for DNA-PKcs expression when compared to the other
PAM50 subtypes (p-value<0.001) (Fig. 5).
We next assessed the expression of the DNA-PKcs gene (PRKDC)
at the transcriptomic level using data from the TCGA invasive
breast cancer cohort8 (Fig. 6a). Higher PRKDC expression is
Published in partnership with the Breast Cancer Research Foundation

signiﬁcantly associated with basal-like PAM50 subtype and ER
negativity (Fig. 6b, c). In addition, high PRKDC expression is also
associated with basal-like gene signature within ER + tumors in
the TCGA cohort (Supplementary Fig. 3). We further validated the
association between PRKDC expression and the basal-like
npj Breast Cancer (2021) 114
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Fig. 2 Analysis of DNA-PKcs expression in the UBC series (n =
300). a Boxplots showing expression levels of DNA-PKc by IHC
according to “core basal status”. High expression of DNA-PKcs is
associated with the core basal IHC phenotype (p-value < 0.05). Core
basal subgroup is deﬁned as ER-, PR-, Her2- and [EGFR + or CK5 + ].
The median (center bar), and the third and ﬁrst quartiles (upper and
lower edges, respectively) are shown. b Scatter plot of CD8 iTIL
expression against DNA-PKcs IHC scores. Each data point represents
one case. The Spearman correlation coefﬁcient (rho) and p-values
are displayed and indicate an overall weak but signiﬁcant
correlation. c Kaplan–Meier curves showing BCSS according to
DNA-PKcs IHC expression status. Abbreviations: IHC immunohistochemistry, iTILs intraepithelial tumor-inﬁltrating lymphocytes, BCSS
breast cancer-speciﬁc survival.
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available Gene Expression Omnibus datasets41 (Fig. 6f). Taken
together, our results show that both DNA-PKcs protein and PRKDC
transcript are biomarkers that help identify basal-like cases both
within ER + and ER- breast cancers.
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DNA-PKcs ( 6) vs DNA-PKcs (<6)
HR=2.04, CI (1.19-3.52)
Log Rank=0.01

Time (years)

PAM50 subtype using data obtained from a contemporary
collection of primary breast cancer tissues from women enrolled
in the SCAN-B trial40 (NCT02306096) (Fig. 6d). High PRKDC was
signiﬁcantly associated with poor disease-free survival rates in the
TCGA cohort (Fig. 6e) and when applying KMplotter to 35 publicly
npj Breast Cancer (2021) 114

PRKDC non-silent somatic mutations are associated with poor
clinical outcomes
We next aimed to correlate our ﬁndings with somatic mutations in
the PRKDC gene encoding for DNA-PKcs. The somatic mutations
previously published from a subset of 640 tamoxifen-treated,
clinically ER + patients from the BC Cancer series were used in this
analysis42 (Supplementary Data 1). Among those cases, 420 cases
also had data for DNA-PKcs expression by IHC generated for the
current study, for which 16 had non-silent and 8 had silent
mutations in PRKDC whereas 396 were wild type. The majority of
non-silent mutations were missense (14/16), with 1 additional
nonsense and 1 frameshift (Fig. 7a). Four of the 14 missense
mutations with available data for IHC DNA-PKcs expression were
predicted to be damaging to the protein function using the
“Mutation Assessor” tool (Supplementary Data 1). When testing
the association between mutation status and DNA-PKcs expression by IHC, the two cases with truncating mutations were
negative for IHC expression (Fig. 7a). In addition, the majority of
cases with missense mutations displayed low expression for DNAPKcs by IHC. A comparison of DNA-PKcs IHC expression between
wild type vs. non-silent mutated cases was insufﬁciently powered
to observe a signiﬁcant association due to the small number of
mutated cases (Fig. 7b).
We further investigated the prognostic implications of PRKDC
somatic mutations in this cohort and found that cases classiﬁed as
having non-silent mutations in PRKDC exhibited signiﬁcantly poor
clinical outcomes when compared to cases characterized with
wild-type PRKDC (HR 2.21, 95% CI 1.08–4.53; p = 0.03) (Fig. 7c). The
TCGA dataset showed non-silent somatic mutations in PRKDC in 8
of 818 cases, which despite limited power showed a similarly
signiﬁcant adverse prognostic association (Fig. 7d). Amongst ERnegative cases, only 2 of 179 in the TCGA cohort and 6 of 233 in
the SCAN-B cohort had PRKDC somatic mutations, numbers too
small for meaningful survival analyses.
DISCUSSION
In this study, we evaluated the prognostic capacity of a basal
subtype biomarker, DNA-PKcs, derived from a published highquality comprehensive proteomic proﬁling study on TCGA breast
cancer samples12. Following prespeciﬁed study design and
methodology adhering to REMARK criteria on both training and
validation cohorts43, we demonstrate, using large cohorts of
clinically-annotated breast cancer cases, that IHC expression of
DNA-PKcs is associated with the basal-like subtype, high-risk
clinicopathological factors, and poor prognosis. These ﬁndings are
consistent with previous reports showing that high expression of
Published in partnership with the Breast Cancer Research Foundation

K. Asleh et al.

5
Table 1. Association of DNA-PKcs expression with clinicopathological
features in the British Columbia Cancer series.
Clinicopathological features

DNA-PKcs expression
(IHC score)
Low (<6)
n = 1783 (%)

High (≥6)
n = 618 (%)

<50

553 (31.0)

217 (35.1)

≥50
Tumor size (cm)

1230 (69.0)

401 (64.9)

≥1
0.06

≤2

915 (51.6)

301 (48.9)

>2

859 (48.4)

314 (51.1)

1&2

783 (45.9)

242 (40.4)

3

922 (54.1)

357 (59.6)

994 (55.9)
785 (44.1)

337 (54.6)
280 (45.4)

0.59

<14%

919 (55.3)

264 (45.8)

<0.001

≥14%

743 (44.7)

313 (54.2)

0.02

Axillary lymph node status

Ki-67 expression

Lymphovascular invasion
938 (54.9)

303 (50.6)

Positive

770 (45.1)

296 (49.4)

ER expression
Negative

397 (22.3)

280 (45.3)

Positive

1381 (77.7)

338 (54.7)

0.07

<0.001

Progesterone receptor expression
Negative

771 (45.7)

326 (55)

Positive

917 (54.3)

267 (45)

<0.001

HER2 expression
Negative

1555 (88.9)

470 (78.1)

Positive
EGFR expression

195 (11.1)

132 (21.9)

Negative

1480 (90.2)

410 (74.3)

Positive

161 (9.8)

142 (25.7)

<0.001

<0.001

CK5/6 expression
Negative

1487 (93)

472 (84.3)

Positive

112 (7)

88 (15.7)

Luminal A ([ER + or PR + ],
HER2-, low Ki67)

786 (47.4)

179 (31)

Luminal B ([ER + or PR + ],
HER2-, high Ki67)

456 (27.5)

111 (19.3)

Luminal B ([ER + or PR + ],
HER2 + )

102 (6.1)

44 (7.6)

<0.001

Breast cancer subtypes

ER−, PR−, HER2 +

89 (5.4)

83 (14.4)

ER−, PR−, HER2−
Core basal subtype

226 (13.6)

160 (27.7)

Yes

121 (7.9)

117 (20.3)

No

1417 (92.1)

460 (79.7)

<0.001

<0.001

Stromal TILs (H&E)
<10%

1401 (83.7)

431 (75.7)

≥10%

272 (16.3)

138 (24.3)

1163 (67.6)

352 (59.4)

<0.001

CD8 iTIL Count
<1

DNA-PKcs expression
(IHC score)
Low (<6)
n = 1783 (%)

High (≥6)
n = 618 (%)

559 (32.5)

241 (40.6)

p-value

Abbreviations: IHC immunohistochemistry, ER estrogen receptor, PR
progesterone receptor, HER2 human epidermal growth factor receptor 2,
EGFR epidermal growth factor receptor, CK cytokeratin, H&E hematoxylin
and eosin, CD cluster of differentiation.

0.26

Tumor grade

Negative

Clinicopathological features

p-value

Age at diagnosis (years)

Negative
Positive

Table 1 continued

<0.001

Published in partnership with the Breast Cancer Research Foundation

PRKDC is associated with poor clinicopathological features and
clinical outcomes in breast cancer at the transcriptomic level19,44.
The association of high expression of DNA-PKcs with poor
clinical outcomes in our cohort was more evident within ER- cases
when compared to ER + . These ﬁndings might be explained by
preclinical studies showing that ER signaling regulates DNA
damage response targets including DNA-PKcs and ATM, with the
majority of ER + tumors displaying relatively low protein expression of DNA-PKcs45. In addition, DNA damage processes are
particularly characteristic of basal tumors, when compared to ER
+ tumors that have less genomic instability8,25,26, thus consistent
with our observation of low overall protein expression of DNAPKcs within the majority of ER + when compared to ER− breast
cancers. Interestingly, a dual role for DNA-PKcs has been further
suggested in preclinical models, as a tumor suppressor in
premalignant stages maintaining genome integrity; while in an
aggressive and advanced stage, DNA-PKcs could indicate high
genomic instability, thus acting as an oncogenic driver23.
A previous study by the Nottingham breast cancer group
reported that IHC expression of DNA-PKcs was signiﬁcantly
associated with good clinical outcomes in breast cancer46. These
observations were mainly seen in the ER + subgroup and as the
authors noted, are contradictory to the preponderance of the preclinical literature showing that DNA-PKcs phosphorylates and
stabilizes ER and hence that low levels of DNA-PKcs would be
expected to contribute to a reduced ER signaling resulting in less
aggressive ER + tumors47–50. Furthermore, the authors noted the
discordance of their outcome associations from those reported in
other transcriptomic studies in breast cancer19,44 and several other
tumors20,21,23,51. The apparent discordance with our current study
and other transcriptomic studies19–21,23,44,51 might be because the
Nottingham study applied data-driven cutpoints to maximize
outcome differences in their data set, in contrast to our study that
applied a prespeciﬁed externally-validated cutpoint on ﬁrst a
breast cancer training and then on a larger independent
validation set. The discordant ﬁndings might also be explained
by the complexity of DNA-PKcs expression due to changes in
protein post-translational modiﬁcations that are involved in the
DNA damage repair process52–54 and could affect the role of ER
signaling in regulating DDR targets including DNA-PKcs45.
In our study, we demonstrated the capacity of DNA-PKcs as a
basal biomarker that is applicable even in the setting of ER
positivity, validated its association with the basal-like
PAM50 subtype and correlated results with PRKDC mutational
status in a large subset of ER + cases. Within the clinically ER +
group, cases with low DNA-PKcs expression were luminal by
PAM50 gene expression while those with a high DNA-PKcs
proﬁled as basal-like.
Proﬁling of the ER + cases for mutations in the PRKDC gene
further showed that non-silent mutations correlated with poor
survival. Interestingly, the original study42 that performed targeted
sequencing on the ER + subset of cases included in this study
reported non-silent somatic mutations in PRKDC to be one of the
npj Breast Cancer (2021) 114
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Fig. 3 Analysis of DNA-PKcs expression in the BC Cancer series (n = 2401). a Boxplots showing the expression levels of DNA-PKcs by IHC
according to “core basal status”. High expression of DNA-PKcs is associated with the core basal IHC phenotype (p-value < 0.001). Core basal is
deﬁned as ER-, PR-, Her2- and [EGFR + or CK5 + ]. The median (center bar), and the third and ﬁrst quartiles (upper and lower edges,
respectively) are shown. b Boxplots showing the expression levels of DNA-PKcs by IHC according to “sTILs” and “CD8 + iTILs” categories. High
expression of DNA-PKcs is associated with high expression of sTILs and high expression of CD8 + iTILs. The median (center bar), and the third
and ﬁrst quartiles (upper and lower edges, respectively) are shown. c Kaplan–Meier curves for BCSS in the BC Cancer series according to DNAPKcs IHC expression status. d Kaplan–Meier curves for BCSS stratiﬁed according to core basal status and DNA-PKcs IHC expression. Core basal
tumors with high DNA-PKcs expression are associated with the worst BCSS. Abbreviations: IHC immunohistochemistry, sTILs stromal tumorinﬁltrating lymphocytes, iTILs intraepithelial tumor-inﬁltrating lymphocytes, BCSS breast cancer-speciﬁc survival.
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Table 2. Multivariate analysis for DNA-PKcs expression in the British
Columbia Cancer series including clinicopathological features,
treatment, and subtype information.
Covariates in the model

a
Core Basal cases in the BC Cancer series
(n=234)

Breast cancer speciﬁc survival
Adjusted HR (95% CI)

p-value

Age at diagnosis
<50

1

≥50

1.07 (0.85–1.36)

0.60

Tumor size (cm)
1

>2
Tumor grade

1.53 (1.29–1.81)

1&2

1

3

1.58 (1.30–1.88)

<0.001

BCSS

≤2

High DNA-PKcs / sTIL+
High DNA-PKcs / sTILLow DNA-PKcs / sTILLow DNA-PKcs / sTIL+

<0.001

Axillary lymph node status
Negative

1

Positive

2.50 (2.00–3.14)

<0.001

Low DNA-PKcs / sTIL+ vs others
HR 0.42, CI 0.22-0.78
Log Rank=0.005

Breast cancer subtypes
Luminal A
Luminal B/Ki67+

1
1.72 (1.40–2.11)

Luminal B/ HER2+

1.78 (1.32–2.41)

HER2+

1.70 (1.26–2.28)

Basal

1.55 (1.17–2.06)

<0.001

Time (years)

b

Adjuvant systemic treatment
0.82 (0.63–1.06)

Chemotherapy only

0.84 (0.62–1.15)

Tamoxifen + chemotherapy
DNA-PKcs IHC expression

0.80 (0.55–1.17)

Low (<6)

1

High (≥6)

1.33 (1.10–1.60)

0.45

Core Basal cases in the BC Cancer series
(n=233)
0.002

HR and 95% CI are derived from multivariable analysis adjusted for age at
diagnosis, tumor size,
tumor grade, nodal status, breast cancer subtypes, and adjuvant systemic
treatments using the Cox regression model. Abbreviations: IHC immunohistochemistry, HR hazard ratio, CI conﬁdence interval.
Breast cancer subtypes: Luminal A, ER + or PR + and Ki-67 < 14%; Luminal
B/Ki67 + , ER + or PR + and Ki-67 ≥ 14%; Luminal B/HER2 + , ER + or PR +
and HER2 + by IHC or FISH; HER2 + , ER- PR- and HER2 + by IHC or FISH;
Basal, triple-negative and EGFR + or CK5 + .

topmost signiﬁcant poor outcome drivers in ER + cases. These
mutations have been further reported to be associated with
downregulated ATM levels55, potentially driving resistance to
endocrine therapy42.
In support of our ﬁndings, mutations in PRKDC have been
previously implicated in breast cancer initiation and progression44,56. In our study, the majority of non-silent mutations
(including both missense and truncating) resulted in a lower
DNA-PKcs protein expression. The majority of PRKDC missense
mutations we identiﬁed would result in either impaired function
or a lower expression of the DNA-PKcs protein. While only a third
of missense mutations were predicted to be damaging, the
majority of other “likely benign” mutated cases still correlated with
poor disease-speciﬁc survival. These ﬁndings suggest that these
mutated cases, being defective for DNA damage repair, are
impaired in their capacity to maintain genomic stability and
consequently evolve to behave aggressively. PRKDC mutant breast
tumors (including those bearing loss-of-function mutations) are

Published in partnership with the Breast Cancer Research Foundation

BCSS

Tamoxifen only

Low DNA-PKcs / CD8iTILHigh DNA-PKcs / CD8iTIL+
High DNA-PKcs / CD8iTILLow DNA-PKcs / CD8iTIL+
Low DNA-PKcs / CD8iTIL+ vs others
HR 0.26, CI 0.13-0.55
Log Rank<0.001

Time (years)

Fig. 4 Prognostic stratiﬁcation of core basal cases by DNA-PKcs
and immune biomarkers in the BC Cancer series. a Within core
basal tumors, the presence of sTILs in combination with low DNAPKcs expression is associated with better BCSS. b Within core basal
tumors, the presence of CD8 + iTILs in combination with low DNAPKcs expression is associated with better BCSS. Abbreviations: IHC
immunohistochemistry, BCSS breast cancer-speciﬁc survival, sTILs
stromal tumor-inﬁltrating lymphocytes, iTILs intraepithelial tumorinﬁltrating lymphocytes.
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IHC expression of DNA-PKcs according to
PAM50 breast cancer subtype in a subset
of the BC Cancer series (n=571)

Kruskal−Wallis, p < 0.001
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Fig. 5 Association of DNA-PKcs expression with PAM50 intrinsic
subtype in a subset of the BC Cancer series. Boxplots showing the
expression levels of DNA-PKcs by IHC across the different PAM50
gene expression intrinsic subtypes. High expression of DNA-PKcs is
associated with basal-like PAM50 subtype (p-value < 0.001). The
median (center bar), and the third and ﬁrst quartiles (upper and
lower edges, respectively) are shown.

characterized by high mutational load and genomic instability56,
suggesting that these tumors should correlate with poor
prognosis regardless of DNA-PKcs protein levels. Since the fraction
of mutated PRKDC tumors in breast cancer is very low (1%), our
main ﬁndings reporting that low expression of DNA-PKcs
correlates with good survival is driven by wild-type tumors. In
this context, DNK-PKcs IHC expression and PRKDC mutation should
be considered in combination to deﬁne a speciﬁc subgroup with
better prognostication.
In relation to treatment, the expression of DNA-PKcs has been
reported to drive resistance to chemotherapy and radiotherapy in
preclinical models19,57, whereas inhibition of DNA-PKcs has been
shown to sensitize breast cancer cells to these treatment
modalities22,24.
DNA-PKcs is a key regulator for maintaining genomic integrity,
cell cycle, and DNA repair through forming complexes with Ku70/
80 to mediate DDR16,18. However, its aberrant high expression in
tumors could be indicative of inherent DDR deﬁcits and high
genomic instability that drive the resistance of these tumors to
chemoradiotherapy. High DNA-PKcs levels have also been shown
to be induced after chemotherapy or radiotherapy treatments in a
manner not dependent on endogenous levels of DNA damage,
but rather on drug-induced levels precipitated by damaging
agents57–60. Thus, the prognostic and predictive capacity of DNAPKcs may well best be assessed on specimens taken from primary
tumors prior to systemic chemotherapy and/or metastatic disease.
In the context of basal-like breast cancer heterogeneity, our
study shows that tumors exhibiting the core basal-like phenotype
npj Breast Cancer (2021) 114

had a higher expression of DNA-PKcs when compared to tumors
characterized as non-core basal. Furthermore, we found a
signiﬁcant association between high DNA-PKcs and high numbers
of TILs and cytotoxic CD8 + lymphocytes. These ﬁndings might be
explained by the high genomic instability that characterizes basal
tumors with high DNA-PKcs expression, resulting in an accumulation of genetic alterations and a consequent high mutational
load61 that could lead to neoantigen production, inducing an
immunogenic antitumor response (basal-like immune hot phenotype). While the process of neoantigen production is an
established consequence of genomic alterations, the immunogenicity of these tumors is highly dependent on the preexisting
inﬂammatory milieu of the host62 and thus the basal subset
exhibiting high expression for DNA-PKcs, but low expression of
sTILs and CD8 iTILs, represents a “basal immune cold” subset. This
basal subset exhibited the worst survival in our study.
To date, the major success made in treating triple-negative
breast cancer patients, with PARP inhibitors targeting the
homologous recombination pathway, has been mainly limited to
a small fraction of patients who harbor BRCA mutations or
homologous recombination pathway defects4,63,64. However,
limited data exist on the role of PARP inhibitors across the diverse
subsets of triple-negative, basal-like and sporadic homologous
deﬁcient breast cancers64,65.
DNA-PKcs, as one of the key proteins involved in the DDR, could
aid in matching basal patients to DNA-PKcs targeting strategies,
DNA-damaging agents, or PARP inhibitors24. Speciﬁcally, since
PARP inhibitors induce the nonhomologous end-joining process
among homologous recombination deﬁcient tumors, DNA-PKcs
could represent a promising therapeutic target in this particular
setting66. Furthermore, with the contribution of the DNA damage
process to high mutational load and antigenicity67, neoantigen
production could be further increased as a result of mutations
induced by DNA damaging agents. It has been shown that in
response to DNA damaging chemotherapy, DDR can promote
signalling pathways resulting in a release of proinﬂammatory
cytokines including type I interferon and nuclear factor-kB68.
Our study has several limitations. While our primary hypothesis
has been tested on large cohorts of patients following a
prespeciﬁed design and scoring methodology, yielding powered
positive results, future studies using samples from clinical trials are
critical to establishing the capacity of DNA-PKcs as a biomarker to
predict beneﬁt from DNA damaging agents, PARP inhibitors and/
or immunotherapies among basal breast cancer patients. Additionally, the prognostic capacity of DNA-PKcs in the context of
basal immune heterogeneity was based on evaluating sTILs and
CD8 + iTILs in these tumors. Given the contribution of many cell
populations, protein components, and their cross-talk to form an
effective anti-tumor immune response, the enumeration of
cytotoxic T cells in tumors is insufﬁcient to characterize complex
immune distinctions. Furthermore, our study included pretreatment specimens from early-stage breast cancer patients; DNAPKcs expression could be upregulated after exposure to chemotherapy or radiotherapy during subsequent tumor progression.
Thus, the prognostic and predictive capacity of DNA-PKcs
expression should be further evaluated after exposure to
chemoradiation particularly amongst basal patients who progress
to metastatic disease.
In conclusion, this study demonstrates the prognostic capacity
of DNA-PKcs, a basal breast cancer biomarker derived from
comprehensive proteomic proﬁling of breast cancer. The integration of DNA-PKcs expression along with established immune
biomarkers stratiﬁes major risk differences within the basal-like
subtype. Such ﬁndings, when applied on clinical trial series would
aid in matching basal patients to DNA-PKcs targeting strategies,
DNA-damaging agents, and their combination with immune
checkpoint blockade.
Published in partnership with the Breast Cancer Research Foundation
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Fig. 6 Analysis of PRKDC expression using publicly-available breast cancer datasets. a Oncoprint outlining the biological classiﬁcations of
825 cases included in the TCGA invasive breast cancer cohort according to ER status, PAM50 subtype, RPPA cluster, and PRKDC mRNA
expression as determined by microarray. b–c Boxplots showing the expression levels of PRKDC, as derived from microarray in the TCGA
invasive breast cancer cohort, is signiﬁcantly associated with basal-like PAM50 intrinsic subtype. The median (center bar), and the third and
ﬁrst quartiles (upper and lower edges, respectively) are shown. c Data were obtained through the cBioPortal for Cancer Genomics database74.
d Raincloud plots showing the expression level of PRKDC, as derived from RNA-seq on the SCAN-B breast cancer cohort, is signiﬁcantly
associated with basal-like PAM50 intrinsic subtype. e–f Kaplan–Meier survival curves showing the association between PRKDC expression and
DFS on cases from the TCGA invasive breast cancer cohort (e) and 35 Gene Expression Omnibus breast cancer datasets (f). Plots were
generated using the bc-GenExMiner v4.575 and the KMplotter analysis platform curated from 35 Gene Expression Omnibus breast cancer
datasets41. Abbreviations: ER estrogen receptor, IHC immunohistochemistry, DFS disease-free survival.
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Fig. 7 PRKDC non-silent somatic mutations are associated with poor clinical outcomes. a Lollipop plot for PRKDC mutations identiﬁed in a
set of 640 tamoxifen-treated, clinically ER + patients. Green-ﬁlled circles denote missense mutation and black-ﬁlled circles denote truncating
mutations. Protein domains are indicated as follows: green, NUC194 domain B in the catalytic subunit of DNA-dependent protein kinases; red,
FAT domain present in the PIK-related kinases; dark-blue, Phosphoinositide 3-kinase (PI3K) domain. A complete description of PRKDC
mutations has been previously published and can be found in Supplementary data 3 of Grifﬁth et al.42. Mutation pathogenicity, clinical
annotation of death due to disease, and DNA-PKcs expression categories by IHC for the corresponding cases are displayed. b Boxplots
showing the expression levels of DNA-PKcs by IHC according to mutation status and its type. The median (center bar), and the third and ﬁrst
quartiles (upper and lower edges, respectively) are shown. c Kaplan–Meier curve for BCSS in the subgroup of ER + cases treated with
tamoxifen in the BC Cancer series according to PRKDC mutation status (n = 409). d Kaplan–Meier curves for OS in the TCGA cohort of invasive
breast cancer according to PRKDC mutation status (n = 818). Abbreviations: ER estrogen receptor, BCSS breast cancer-speciﬁc survival, OS
overall survival, IHC immunohistochemistry.
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METHODS
Study cohorts
Two independent, well-annotated cohorts corresponding to patients
diagnosed with stage I–III breast cancer were included in the current
study. The staining protocol, scoring criteria, and clinical data analysis were
ﬁrst evaluated on a set of female patients diagnosed with invasive breast
cancer (n = 330) at the University of British Columbia (UBC) hospital
between 1998–2002, designated as the UBC series. The second cohort was
used for subsequent detailed analyses and is comprised of primary
invasive breast cancer cases diagnosed in the province of British Columbia
at the British Columbia Cancer Agency between 1986–1992, referred to as
the BC Cancer series. These patients were treated in accordance with the
provincial guidelines during the speciﬁed time period. The characteristics
of these cohorts have been described previously28,29.
Patients diagnosed with ductal carcinoma in situ only, metastatic
disease at presentation, and those who received neoadjuvant therapies
were excluded.

Ethics approval and study design
This study was approved by the research ethics board of UBC and the BC
Cancer Breast Cancer Outcomes unit (approval number: H17-01207). The
current hypothesis-based retrospective biomarker study was conducted in
accordance with the Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) guidelines43. Prespeciﬁed assessment criteria
were used for IHC scoring of the biomarkers of interest. Potential
hypotheses were initially tested in the UBC series, with the independent
BC Cancer series used for subsequent validation studies following a formal
prespeciﬁed analysis plan approved at a meeting of the Breast Cancer
Outcomes Unit at BC Cancer. Consent for the use of previously assembled
patient specimens was obtained under a waiver of informed consent
policy without identiﬁcation of patient information.

Tissue microarrays and immunohistochemistry
Formalin-ﬁxed parafﬁn-embedded tumor blocks of primary surgical
specimens were used to construct a series of 0.6 mm core tissue
microarrays (TMAs) for both study cohorts as described previously69. For
the UBC series, duplicate 0.6 mm cores were extracted from each
pathology block and embedded into three TMA recipient blocks, while
seventeen TMA blocks needed to be constructed to represent the BC
Cancer series (1 core per patient)69. Serial 4μm sections from these TMAs
were previously stained for the following IHC biomarkers included in this
study: ER, progesterone receptor, HER2, Ki-67, cytokeratin (CK5/6), and
EGFR. The detailed protocols for IHC staining, scoring criteria of these
biomarkers, and deﬁnitions of IHC-based breast cancer subtypes have
been described previously31. Stromal tumor-inﬁltrating lymphocytes were
assessed as per recommendations of the International TIL Working
Group70. To assess the suitability of TMAs for assessing stromal tumorinﬁltrating lymphocytes (sTILs), we scored sTILs on digitized full-face
hematoxylin and eosin (H&E) stained sections and corresponding 0.6 mm
TMA cores from 317 cases from the BC Cancer series. A good correlation
(spearman rho = 0.67) was observed (Supplementary Fig. 4). Hence for
further analyses TMAs were utilized with a 10% cutoff as described
previously71. In addition, TMA sections were scored for CD8 + TILs in the
intraepithelial compartment (iTILs) using established, analytically validated
IHC staining and interpretation methods as previously published by our
group72,73. We chose to analyze CD8 + iTILs based on previous observations that this biomarker could deﬁne the relevant subset of cytotoxic
immune cells that drives anti-tumor immune response and associates with
good prognosis72. Array sections at 4 µm were mounted on glass slides
and baked for an hour at 60 °C to prepare for staining on a Ventana
Discovery XT automated stainer (Ventana Medical Systems, Tucson, AZ).
Antigen retrieval was performed using Cell Conditioning 1 antigen retrieval
(Ventana Medical Systems) followed by 2 h of primary antibody incubation
at room temperature, and detected using a ChromoMap DAB Detection Kit
(Ventana Medical Systems). IHC staining of DNA-PKcs was performed with
anti DNA-PKcs rabbit monoclonal primary antibody (clone Y393, dilution
1:500, Abcam, cat# ab32566). Slides were then incubated with a secondary
antibody (UltraMap anti-Rb HRP) for an additional 16 min. Separate TMAs
that included normal breast, breast, and ovarian cancer tissues were used
as positive controls. The stained TMA slides were digitally scanned and
DNA-PKcs nuclear expression in the tumor cells was visually scored by a
pathologist blinded to clinical data.
Published in partnership with the Breast Cancer Research Foundation

Scoring of DNA-PKcs was performed following published criteria
previously employed by other groups, using an IHC scoring system based
on the proportion and intensity of nuclear staining observed in the
invasive carcinoma cells30. The positivity proportion scores were captured
as a continuous variable for each core and then categorized into four
scores as follows: 0, no positive tumor cells; 1, <10%; 2, 10–34%; 3, 35–74%,
and 4, ≥75%. The staining intensity was reported as weak (1), moderate (2),
or strong (3). The IHC score was computed by multiplying the proportion
of positive cells (categorized as 1–4) by the intensity score. This computed
IHC score ranged from 0–12 and was used for the ﬁnal scoring of DNA-PKcs
by IHC. For cases with duplicate cores, the higher IHC score was used for
analysis. Low expression of DNA-PKcs was deﬁned as an IHC score of <6
whereas a score ≥6 was assigned to tumors with high expression of DNAPKcs. All slides were scanned digitally using a Bliss System (Bacus
Laboratories/Olympus America, Lombard, IL, USA).

STATISTICAL ANALYSIS
IBM SPSS (version 25) and R statistical software were used for
performing statistical analyses. Descriptive statistics were computed for continuous and categorical variables. The assessment of
IHC expression scores against categorical groups was performed
using the two-sided Wilcoxon rank-sum test for pair-wise
comparisons and the Kruskal–Wallis rank-sum test for comparisons among more than two groups. Chi-square or Fisher exact
tests were used to assess associations between DNA-PKcs
expression and clinicopathological variables or expression of
other biomarkers. Survival analysis was performed using breast
cancer-speciﬁc survival (BCSS) as the prespeciﬁed primary endpoint, deﬁned as the period between the date of diagnosis and
the date of death attributed to breast cancer. Patients who were
alive at the end of the follow-up period or who died due to causes
other than breast cancer were censored. Cumulative survival
probabilities were estimated by Kaplan-Meier methodology and
differences in the survival rates between groups were calculated
by log-rank testing. Cox proportional hazard modelling was used
to compute univariate and multivariate analyses; hazard ratios
with 95% conﬁdence intervals were reported for each variable.
Multivariate analysis was adjusted for clinicopathological variables
including age at diagnosis, tumor size, grade, and nodal status.
P-values of less than 0.05 were considered statistically signiﬁcant.
Bioinformatic analyses using publicly-available breast cancer
datasets
The expression of PRKDC mRNA was assessed at the transcriptomic level using the TCGA cohort of breast invasive carcinomas8
and the Sweden Cancerome Analysis Network - Breast (SCAN-B)
cohort40 (NCT02306096). TCGA data including PRKDC expression,
PAM50 subtypes, reverse phase protein assay (RPPA) clusters, and
IHC ER status were obtained through cBioPortal74. SCAN-B was
accessed using the bc-GenExMiner v4.5 publicly-available tool75.
Survival analyses for PRKDC mRNA expression were performed
using the bc-GenExMiner v4.5 and the previously-established
KMplotter analysis platform41 curated from 35 Gene Expression
Omnibus datasets accessed using https://kmplot.com/analysis/.
Kaplan–Meier survival curves were generated by partitioning cases
according to the median mRNA expression.
Analysis of PRKDC mutation data
Somatic mutations in a subset of 640 tamoxifen-treated, clinically
ER + primary tumors from the BC Cancer series were available
from a previous study that performed targeted sequencing of 83
biologically important genes including PRKDC42. Mutation lollipop
diagrams were generated using the cBioPortal Mutation Mapper
tool. Functional categorizations of PRKDC mutations were assessed
using the “Mutation Assessor” with information using PolyPhen76
and SIFT77 tools.
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Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
An anonymized data ﬁle containing immunohistochemical data, molecular
PAM50 subtype, and PRKDC mutation data used and analyzed in this study can be
found in Supplementary Data 1. Clinical data for the patients included in this study
are not publicly available per policy to protect patient privacy. Clinical data access
can be made available to qualiﬁed researchers on a reasonable request through the
Breast Cancer Outcomes Unit of BC Cancer, upon completion of a Data Transfer
Agreement and conﬁrmation of ethical approval. Reasonable requests or queries
should be directed to the corresponding author.
This study involved the collection and analysis of data from multiple publicly-available
datasets. The TCGA breast cancer data analyzed can be accessed through the
cBioPortal for Cancer Genomics repository (https://www.cbioportal.org/) - unique
identiﬁer: “Breast Invasive Carcinoma (TCGA, Nature 2021)”. SCAN-B was accessed using
the bc-GenExMiner v4.5 publicly-available tool (http://bcgenex.centregauducheau.fr) –
unique identiﬁer: http://bcgenex.ico.unicancer.fr/BC-GEM/GEM-requete.php “RNA-seq/
SCAN-B/PRKDC”. Survival analyses for PRKDC mRNA expression were performed using
the bc-GenExMiner v4.5 and the previously-established KMplotter analysis platform
accessed using (https://kmplot.com/analysis/) – unique identiﬁer: https://kmplot.com/
analysis/index.php?p=service&cancer=breast
“PRKDC/Affymetrix_ID
208694_at”.
PRKDC full genomic data and methods used for targeted sequencing can be found
in Supplementary Data 3 of Grifﬁth et al.42 (available online) – unique identiﬁer: https://
www.nature.com/articles/s41467-018-05914-x#Sec25 “Supplementary Data 3”.

CODE AVAILABILITY
No custom code was generated to collect data in this study. R codes used for analysis
in this study are available from the corresponding author on a reasonable request.
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